Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 109,029

Document Document Title
WO/2016/009066A1
The present invention relates to a compound of formula (1) in the form of a base or addition salt with an acid, particularly a pharmaceutically acceptable acid. It further relates to a pharmaceutical composition comprising said compound ...  
WO/2016/010108A1
A compound represented by formula (I) [in the formula: (1) represents (2), (3), etc.; R2a represents optionally substituted alkyl, etc.; R2b, R3a, R3b, R4a, R4b, R5a and R5b independently represent a hydrogen atom, etc.; and R1 represent...  
WO/2016/011270A2  
WO/2016/010092A1
Provided are: a compound that is useful as an amyloid oxidation catalyst which can be applied inside a living body and can be applied not only to Aβ peptides but also to other amyloids; and an amyloid-related preventive or therapeutic d...  
WO/2016/007729A1
Provided herein are drug products comprising a combination of an opioid receptor agonist and an opioid receptor agonists, including co-packaged drug products comprising an opioid receptor agonist and an opioid receptor antagonist in a de...  
WO/2016/007630A1
Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.  
WO/2016/005419A1
The present invention is directed to new compounds of formula (I) selectively binding the cannabinoid 2 receptor. In addition, the invention relates to the use of said compounds for determining cannabinoid receptor 2 (CB2)-selective rece...  
WO/2016/006593A1
Provided are an amyloid fibril formation inhibitor and a therapeutic or prophylactic drug for neurodegenerative diseases, said inhibitor and drug comprising a compound represented by general formula (I), a pharmaceutically acceptable sal...  
WO/2016/007762A1
Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumati...  
WO/2016/005923A1
The disclosure relates to processes for reducing the amount of a compound of formula (I) or a salt or a solvate thereof present in a composition comprising compounds of formulae (I) and (II) or a salt or a solvate thereof.  
WO/2016/004908A1
The new method of preparing 1-(2-(2,4-dimethylphenylsulphanyl)pheny!)piperazine of formula (I) or its salt comprises a reaction of 2-(2,4-dimethylphenylsulphanyl)benzeneamine of formula (XI), wherein Me is methyl, with a suitable precurs...  
WO/2016/007616A1
The present invention provides methods for treating a neurological disorder comprising administering to a patient in need thereof a dose of VX-745, or a pharmaceutically acceptable composition thereof, providing a blood concentration of ...  
WO/2016/004882A1
Provided herein are aromatic heterocyclic derivatives or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof used for treating Alzheimer's disease. Also provided herein...  
WO/2016/006947A1
The present invention relates to: a pharmaceutical composition for preventing or treating neurodegenerative diseases, containing a Humulus japonicus extract, which has an inhibitory effect on dopaminergic neuron death, an effect of prote...  
WO/2016/007966A2
Imidazolyl-pyrimidine and related compounds, as can utilize heme-iron coordination in the selective inhibition of neuronal nitric oxide synthase.  
WO/2016/007414A1
The present invention relates to antibody-based probes (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically...  
WO/2016/004121A1
The invention described herein relates to a cannabis cultivar that produces high concentrations of cannabidiol. The invention further relates to preparations and products derived from the cannabis cultivar. Also provided are methods of t...  
WO/2016/001417A1
The present invention relates to anti- metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.  
WO/2016/004055A1
The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments de...  
WO/2016/000265A1
Disclosed is a use of phthalide compound for the preparation of a medicament. The medicament is especially used for treating and/or delaying the degeneration of Purkinje cells, and the phthalide compound is selected from the following gr...  
WO/2016/003450A1
The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula I or II or a stereoisomer, tautomer, racemic, metabolite, pro- or pre-drug, salt, hydrate, or solvate thereof, wherein Ar, Cy, R1, R3, p an...  
WO/2016/003296A1
The invention relates to compounds of general formula (I) wherein: one of A1 and A2 represents a nitrogen atom and the other a carbon atom optionally substituted by halogen; the wave line between the sulfonamido moiety and B/C rings repr...  
WO/2016/002827A1
A therapeutic agent for progressive demyelinating immune disease containing as an effective component thereof an anti-CD27 antibody, an antigen-binding fragment thereof, an anti-CD226 antibody, or an antigen-binding fragment thereof; a t...  
WO/2016/001266A1
The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the prese...  
WO/2016/001398A1
The present invention relates to a novel polymorphic form of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropr opoxy)benzylamine hydrochloride.  
WO/2016/002926A1
 An objective of the present invention is to provide a new oxytocin derivative that has a more sustained effect in the body, and a drug composition containing said compound. The objective is met by providing: a new oxytocin derivativ...  
WO/2016/003067A1
The present invention relates to a pharmaceutical composition for suppressing cell transplant rejection, the composition containing a high mobility group box 1 A domain (HMGB1A) as an active ingredient. The use of the composition of the ...  
WO/2016/001390A1
The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof Formula (I), and its uses to treat a disorder associated with protein misfolding stress and in particular with an...  
WO/2016/003169A2
The present invention relates to a composition for inducing cell reprogramming. The indazole derivative compound contained in the composition of the present invention shows an improved biological profile and at the same time can perform ...  
WO/2016/002854A1
Provided are: a preparation which can be used for the promotion of the proliferation of neural stem cells, a preparation which can be used for the prevention or treatment of diseases associated with the decrease in neural stem cells, a p...  
WO/2016/002948A1
The purpose of the present invention is to provide a lysophosphatidylserine derivative or salt thereof. The present invention provides a lysophosphatidylserine derivative or salt thereof, and a pharmaceutical composition or lysophosphati...  
WO/2016/001643A1
The present invention relates to dietary supplements, medical foods, or pharmaceutical compositions for use in the enhancement of cognitive function in healthy subjects and/or subjects person suffering from a cognitive deficit, comprisin...  
WO/2016/000361A1
Provided is an application of oxiracetam or levo oxiracetam for preparing a drug preventing or treating neurofunction deficit. Experimental results show that oxiracetam has a noticeable effect as a treatment for ischemic neurofunction de...  
WO/2016/001345A1
The present invention relates to new tricyclic triazolic compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to ...  
WO/2015/200195A1
This invention relates to methods of stimulating the activity of the human and animal enteric nervous system. The method comprises orally administering an aminoserol, such as squalamine, a naturally occurring aminosterol isolated from Sq...  
WO/2015/196401A1
Disclosed is a use of α-Asarone in preparing drugs for preventing and treating Alzheimer's disease. As indicated by the experiments, α-Asarone has an obvious inhibiting effect on palsy phenotype in pathological models of animals with A...  
WO/2015/197098A1
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...  
WO/2015/197079A1
The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders.  
WO/2015/200594A2  
WO/2015/200322A1
In certain embodiments, the invention relates to methods for treating migraine (e.g. episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal...  
WO/2015/199537A1
The invention relates to the field of therapies for and prevention of mental disorders, more particularly therapies for depression, burn-out and cognitive disorders. Specifically, the invention relates to a new mineral composition compri...  
WO/2015/198078A1
The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and / or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly p...  
WO/2015/197735A1
Herein is reported a non-covalent complex of a haptenylated antibody that specifically binds to human Tau(pS422) and an anti-blood brain barrier receptor/hapten bispecific antibody.  
WO/2015/200534A2
Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.  
WO/2015/199206A1
The present invention relates to a compound represented by formula (I), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound or the salt. (In the formula, R1 represents a hydrogen atom or t...  
WO/2015/199234A1
 Provided is a novel salt of an α-halogen-substituted thiophene compound that has powerful LPA receptor antagonistic action and that is useful as a pharmaceutical product. A salt represented by general formula (1) [In the formula: R...  
WO/2015/196402A1
A preparation method for a traditional Chinese medicine composition and use thereof in preparing medicines for prevention or treatment of Alzheimer's disease. The traditional Chinese medicine composition mainly comprises the following ac...  
WO/2015/200472A1
Embodiments of the invention relate generally to the field of transdermal delivery and more specifically to transdermal patches containing rasagiline for the treatment of depression, Parkinson's disease, and other nervous system conditions.  
WO/2015/200766A2
The present invention provides compounds and compositions which are positive allosteric modulators of GABA-A receptors that selectively target the peripheral nervous system and organs of the body, and which do not pass through the blood-...  
WO/2015/199503A1
The present invention relates to a pharmaceutical composition for preventing and treating degenerative brain diseases, containing 5-[(3-chlorophenyl)amino]benzo [c]-2,6-naphthyridine-8-carboxylic acid (CX-4945) as an active ingredient. S...  

Matches 51 - 100 out of 109,029